Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy

Tristan D. Yan, Oswald A. Stuart, Dal Yoo, Paul H. Sugarbaker*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

23 Citations (Scopus)


The treatment of peritoneal surface malignancy mainly focuses on diffuse malignant peritoneal mesothelioma, pseudomyxoma peritonei from appendiceal cancer, and peritoneal dissemination from gastrointestinal and ovarian cancers. Cancer progression causes peritoneal implants to be distributed throughout the abdominopelvic cavity. These nodules plus the ascitic fluid result in abdominal distension. As the disease progresses, these tumors cause intestinal obstruction leading to debilitating symptoms and a greatly impaired quality of life. In the past, the prognosis of patients with peritoneal surface malignancy was regarded dismal and cure was not an option. Recently, cytoreductive surgery combined with perioperative intraperitoneal chemotherapy has shown an improved survival in selected patients with this disease. To date, multiple different treatment regimens of perioperative intraperitoneal chemotherapy have been used. This review focuses on the perioperative intraperitoneal chemotherapy currently in use in conjunction with cytoreductive surgery for the treatment of peritoneal surface malignancy at the Washington Cancer Institute.

Original languageEnglish
Article number17
Pages (from-to)1-7
Number of pages7
JournalJournal of Translational Medicine
Publication statusPublished - 10 Apr 2006
Externally publishedYes


Dive into the research topics of 'Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy'. Together they form a unique fingerprint.

Cite this